Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

Next Previous
Trial Profile

A Phase 2a, Double-blind, Placebo-controlled, Multi-center, Randomized Study Evaluating LSTA1 When Added to Standard of Care (SoC) Versus Standard of Care Alone in Subjects With Advanced Solid Tumors (BOLSTER)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cerepetide (Primary) ; Cisplatin; Docetaxel; Durvalumab; Gemcitabine; Paclitaxel
  • Indications Cholangiocarcinoma; Gallbladder cancer; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oesophageal cancer; Oropharyngeal cancer; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms BOLSTER
  • Sponsors Lisata Therapeutics

Most Recent Events

  • 07 Aug 2025 According to a Lisata Therapeutics media release, company decided to stop enrollment at approximately 20 patients to accelerate data readout and optimize capital allocation in the second-line CCA cohort .
  • 07 Aug 2025 According to a Lisata Therapeutics media release, topline data readout to fourth quarter of 2025.
  • 06 Jun 2025 Planned End Date changed from 1 Mar 2026 to 1 Mar 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top